Albany Molecular Research (amri)

  • ANNUNCIO: Segui le NewsLetter di

    Al via la Newsletter di Borse, con tutte le notizie quotidiane sui mercati finanziari. Iscriviti per rimanere aggiornato con le ultime News di settore, quotazioni e titoli del momento.
    Per iscriverti visita questo link.


Punti reazioni
Faccio un nuovo thread perchè non riesco a trovare il vecchio. Fortuna che sono uscito un mesetto fa da questo titolo. Oggi vedo addirittura un 14,53 con un -10,53%:eek:

Albany Molecular Research Inc., down $1.52 at $14.72

The company said it would close a research facility due to weak demand.
PRESS RELEASE: Albany Molecular Research, Inc. Reports First Quarter 2004 Result [DHVJKDM]

ALBANY, N.Y.--(BUSINESS WIRE)--May 4, 2004--Albany Molecular Research, Inc.
(Nasdaq: AMRI) today reported financial results for the quarter ending March 31,
2004. Concurrently, the company announced plans to close its Mount Prospect
Research Center and consolidate those operations and technologies into existing
space at its New York facilities.

First Quarter 2004 Results

Total revenue for the first quarter of 2004 decreased by $4.1 million, or
9.2%, to $40.8 million, compared to $44.9 million in the first quarter of 2003.
Total contract revenue for the first quarter of 2004 decreased by $3.0 million,
or 8.9%, to $30.8 million, compared to total contract revenue of $33.8 million
during the first quarter of 2003. During the quarter, one of the company's
customers adjusted its quarterly delivery requirements, resulting in a shift to
the third and fourth quarters of 2004 of $3.0 million in contract revenue that
had originally been anticipated to be recorded in the first quarter. Recurring
royalties for the first quarter of 2004 were $10.0 million, a decrease of $1.1
million, or 10.0%, from recurring royalties of $11.1 million in the first
quarter of 2003. AMRI earns royalties from worldwide sales of the non-sedating
antihistamine Allegra(R) (Telfast(R) outside the United States) for patents
relating to the active ingredient in Allegra.
Contract revenue for AMRI, excluding its Organichem division, for the first
quarter of 2004 was $14.1 million, a decrease of 10.5% compared to contract
revenue of $15.7 million during the first quarter of 2003. Gross profit margin
for AMRI's contract business, excluding its Organichem division, declined to
26.4%, compared to 35.6% in the first quarter of 2003, reflective of the fixed
cost components of AMRI's contract business.
Contract revenue at AMRI's Organichem division in the first quarter of 2004
was $16.7 million, a decrease of 7.6% compared to contract revenue of $18.1
million during the first quarter of 2003. As stated above, due to a revised
delivery schedule, $3.0 million worth of shipments were shifted by one customer
from the first quarter and are expected to ship in the third and fourth quarters
of 2004. The customer's full year production requirements have not changed,
however. Gross profit margin for Organichem in the first quarter of 2004 was
19.4%, compared to 12.3% in the first quarter of 2003. The improvement in
Organichem's gross margin is primarily attributable to cost reduction efforts
implemented subsequent to AMRI's acquisition of Organichem.
During the first quarter of 2004, AMRI recorded a $3.1 million, or $0.06 per
diluted share charge related to the issuance to Bristol-Myers Squibb (BMS) of
warrants to purchase up to 516,232 shares of AMRI common stock, with exercise
prices ranging from $30.24 to $35.24. The issuance of these warrants results
from a 2002 agreement whereby BMS transferred intellectual property to AMRI,
providing AMRI with ownership of one of BMS's preclinical drug candidates, along
with patent applications covering Attention Deficit Hyperactivity Disorder
(ADHD) and central nervous system indications. In connection with the agreement,
in March 2004, AMRI elected to retain ownership of the technology and all
improvements made to date by AMRI, resulting in the issuance of the warrants to
BMS. The issuance of these warrants satisfies all equity-related obligations to
BMS and results in AMRI's full ownership of these preclinical drug candidates
and related intellectual property. The $3.1 million charge was included on
AMRI's financial statements under research and development costs.
Including the $0.06 per share warrant issue expense, net income under U.S.
Generally Accepted Accounting Principles (U.S. GAAP) in the first quarter of
2004 was $2.8 million, or $0.09 per share on a diluted basis, compared to net
income in the first quarter of 2003 of $4.1 million, or $0.13 per share on a
diluted basis. During the first quarter of 2003, AMRI recorded a one-time, $1.4
million charge related to the termination of the company's lease in Iowa, as
well as a $300,000 purchase accounting expense related to AMRI's acquisition of
Organichem. The one-time charge of $1.4 million and the purchase accounting
expense of $300,000 represented $0.03 per diluted share in the first quarter of
AMRI Chairman, President and Chief Executive Officer Thomas E. D'Ambra, Ph.D.
said, "During the first quarter and for the near future, we note a softening of
demand in certain segments of our services business. The amount of foreign
competition and their substantially reduced business costs means that AMRI finds
itself in an increasingly competitive environment for many of our services.
Demand for many of our services remains strong, however. We intend to capitalize
on our strengths, seek aggressively to control costs, and implement new
initiatives that deal with the realities of today's marketplace. AMRI is
continuing to execute its business strategy, and we make these changes with an
eye toward the long-term success of the company. As we compete globally to
maintain a leading position in our industry, we hope that the synergies and
efficiencies afforded by these moves today will be a first step on a return to
sustained growth."
The total number of employees at AMRI at the end of the first quarter of 2004
was 835. At March 31, 2004, AMRI had cash, cash equivalents and investments of
$128.1 million, compared to $124.6 million at December 31, 2003. The net
increase of $3.5 million in cash, cash equivalents and investments in the first
quarter of 2004 was due primarily to cash generated from operations of $9.7
million, offset by $5.8 million in purchases of property plant and equipment.
Total long-term debt at March 31, 2004 was $56.6 million, compared to $57.6
million at December 31, 2003. Total common shares outstanding at March 31, 2004
were 31,712,454.

Facility Consolidation

The company has also announced plans to consolidate operations and
technologies at its Mount Prospect Research Center (near Chicago, IL) with
existing facilities in New York. Technologies at Mount Prospect include
biocatalysis, drug metabolism screening, research fermentation and a portion of
AMRI's chemical development synthesis group. This consolidation will result in
the closure of the Mount Prospect Research Center, which is anticipated to occur
during the third quarter of 2004. The company has offered relocation
opportunities to a number of Mount Prospect employees, primarily those in
scientific and technical positions.
The closing of this facility is expected to result in up to $5 million in
pre-tax annual cost savings, beginning in 2005. AMRI expects to incur
restructuring charges of approximately $2.5 million to $3.5 million during the
second and third quarters of 2004. Subject to an appraisal of the fair market
value of the real property and equipment, AMRI expects to record up to $4.5
million in disposition and impairment costs related to the closure of the Mount
Prospect facility. As of March 31, 2004, the carrying value of the real property
and equipment at the Mount Prospect facility was $9.0 million. The disposition
and impairment costs are anticipated to be recorded in the second quarter of
D'Ambra added, "As our industry evolves, we continue to be faced with new and
tough challenges. The decision to consolidate and relocate operations from Mount
Prospect was extremely difficult, but necessary in light of the current economic
climate for our industry. At the time we purchased the facility in 2001, we
anticipated continued growth in our contract chemistry business and our
headcount, and the facility provided considerable room for expansion, as well as
access to many leading educational centers and sources of potential new
recruits. While revenue from AMRI's chemical development business has increased
since 2001, growth in this portion of our business has not kept pace with
earlier expectations. We continue to see much promise in our biocatalysis and
bioscience technologies, and believe that relocating these technologies from
Mount Prospect to New York should provide opportunities to more fully integrate
and develop even greater synergies with AMRI's medicinal chemistry and other
discovery technologies. In addition, transferring our Mount Prospect-based
chemical development operations will result in greater efficiencies and provide
closer proximity to our upstate New York R&D and manufacturing facilities."
D'Ambra continued, "In addition, while AMRI has offered relocation to a number
of employees, we recognize the hardship brought about to many of our employees
by the closing of this facility, and I want to assure those employees that we
will do whatever we can to provide assistance during this difficult transition
period. I want to thank all of the employees in Mount Prospect for their efforts
and contributions. I also want to assure all AMRI customers with ongoing
projects in Mount Prospect that there will be no delay in deliveries or customer
commitments as a result of this consolidation."

Earnings Guidance

AMRI Chief Financial Officer David P. Waldek updated previous financial
guidance for the full year 2004. Mr. Waldek said, "Based on the industry's focus
on mid-to-late stage development projects, we project a continued softness in
the demand for our traditional medicinal chemistry contract services.
Accordingly, we are projecting our 2004 contract revenues to range from $133 to
$138 million, compared to our previous guidance of $143 to $148 million. As
indicated by the closure of our Mount Prospect facility, we are aggressively
seeking to control costs. This consolidation is estimated to result in annual
pre-tax savings of $5 million beginning in 2005."
(MORE) Dow Jones Newswires
05-04-04 0837ET- - 08 37 AM EDT 05-04-04

(C) Dow Jones & Company, Inc. All rights reserved.

04mag04 12:37 GMT
altro -9%:eek: Da studiare a questo punto
chiusura poco sopra ma che non lascia prevedere nulla di buono:rolleyes:
Inisider venditori. Con una dirigente che si chiama kuhla sanno chi incolpare nelle situazioni difficili:D
Transaction Date Name Transaction Num. of Shares Price Proceeds
2 March 2004 Kuhla Donald E Gift 2,000 15.15 to 15.15 $30,300
19 February 2004 Grates James J Sell 895 16 to 16 $14,320
19 February 2004 Kuhla Donald E Sell 20,000 15.946 to 15.946 $318,920
19 February 2004 Kuhla Donald E Exercise 45,000 0.915 to 0.915 $41,175
18 February 2004 Trova Michael P Sell 40,000 16 to 16 $640,000
12 February 2004 Haydu Frank W III Sell 5,526 16 to 16 $88,416
12 February 2004 Haydu Frank W III Exercise 3,751 4.44 to 4.44 $16,654
5 December 2003 Waldek David P Sell 15,000 14.26 to 14.26 $213,900
5 December 2003 Waldek David P Exercise 17,000 10 to 10 $170,000
4 December 2003 Kuhla Donald E Sell 10,000 14.5 to 14.5 $145,000
4 December 2003 D Ambra Constance M Gift 50,000 14.295 to 14.295 $714,750
4 December 2003 D Ambra Thomas E Gift 50,000 14.295 to 14.295 $714,750
2 December 2003 Meckler Harold Sell 5,300 14.5 to 14.5 $76,850
1 December 2003 D Ambra Thomas E Gift
Un doppio minimo su base biennale e forse in procinto di un minimo assoluto:)


  • mchartisapi.png
    21,7 KB · Visite: 174
cosa sta succedendo a questo titolo? Messo piuttosto maluccio:rolleyes:


  • mchartisapi.png
    20,8 KB · Visite: 163
dal triennale sembra che stia ricominciando ad accumulare ai minimi;)


  • mchartisapi.png
    20,8 KB · Visite: 178
non c'è denaro

oggi 18492

veramente ridicolo:confused: :confused:
  • Like
Reazioni: sat
Scritto da gianni longo
non c'è denaro

oggi 18492

veramente ridicolo:confused: :confused:
bisogna rimettersi a studiare la questione. Se mantiene questo trend basta una buona notizia ed è capace di schizzare;)
adesso viaggia attorno ai minimi annuali. Credo che abbia un p\e superiore a google:D
P/E (TTM) 977.78 +6.610.90%
ritornata nelle grazie degli investitori?;) vedo un +7% 10,99 dopo aver fatto una puntata a 13$:eek:
i risultati non sembrano particolarmente brillanti:rolleyes: Comunque la compagnia ritiene che il peggio sia passato:rolleyes:
Molecular 3Q Net Falls, Sees Narrower Year Loss
E-mail or Print this story

8 November 2004, 11:49am ET

ALBANY, N.Y. (Dow Jones)--Albany Molecular Research Inc.'s (AMRI) third- quarter net income fell as the company's services business faced tight customer budgets, softer demand and competition from low-cost offshore alternatives.

In a press release Monday, the research and drug development company said it expects a narrower loss for the full year, but will restate results for the last three years because of an overstatement of interest income.

For the third quarter, Albany's net income fell to $2.9 million, or 9 cents a share, from $8.2 million, or 25 cents a share, a year earlier. The latest quarter includes a charge of 2 cents a share for relocation and severance costs related to the company's research center near Chicago.

Analysts polled by Thomson First Call, on average, expected the company to earn 9 cents a share in the latest quarter.

Third-quarter revenue fell 6% to $40.6 million from $45.4 million.

However, the company believes the worst of the recent decline in business is over.

Albany Molecular's third-quarter earnings beat its own estimates of 4 cents to 5 cents a share, including charges.

Albany projects fourth-quarter earnings of 16 cents to 17 cents a share, while Wall Street projects earnings of 16 cents. In the year-earlier period, the company earned 33 cents a share.

The company projects fourth-quarter contract revenue of $31 million to $35 million.

For the full year, Albany expects its loss to narrow to 30 cents to 31 cents a share, compared with its previous projection of a loss of 34 cents to 37 cents a share. In 2003, Albany earned 96 cents a share.

The 2004 projection includes charges of 7 cents a share for the issuance of warrants, costs of 11 cents a share for the consolidation of the research facility, and charges for the reductions in asset carrying value of 73 cents a share.

Analysts expect earnings of 58 cents a share for the full year.

For the full year, Albany continues to project corporate contract revenue of $ 119 million to $123 million.

During a review of the company's financial results, Albany Molecular discovered that the accounting treatment for the amortization of premiums and discounts on certain bond investments has been inaccurate in the financial statements since 2001.

As a result of this error, interest income was overstated for the three years before Dec. 31, 2003.

Although the company believes the impact of the error was not material to any previously issued financial statements, Albany decided the cumulative adjustment required to correct this error would be significant to operating results in 2004, and therefore the company should restate its previously issued financial statements.

The company plans to file a Form 10-K/A later Monday and will include a restatement of its audited financial statements for 2001, 2002 and 2003. Albany Molecular Research Inc. - Albany, N.Y.

3rd Quar Sept 30:

2004 2003 Revenue $40,620,000 $45,405,000 Net income a 2,890,000 8,233,000 Shr earns

Net income a .09 .25

a. Includes a charge of 2 cents a share for relocation and severance costs related to the company's research center near Chicago.

-Anjali Cordeiro; Dow Jones Newswires; 201-938-5400;

Dow Jones Newswires
occhio a questa. Presenterà i risultati domani prima dell'apertura dei mercati
, Inc. to Announce Fourth Quarter Results
E-mail or Print this story

28 February 2005, 5:12pm ET

ALBANY, N.Y.--(BUSINESS WIRE)--Feb. 28, 2005--Albany Molecular Research, Inc. (Nasdaq: AMRI) will report fourth quarter 2004 results before the opening of the market on Thursday, March 3, 2005. The company will hold a conference call at 3:00 p.m. Eastern Time to discuss its quarterly financial results.

Mentioned Last Change
AMRI 10.01 0.03dollars or (0.30%)
If you are interested in listening to the conference call, please dial 800-299-7098 (for domestic calls) or 617-801-9715 (for international calls) at 2:45 p.m. and use passcode 44243845. In addition, the call is being webcast on the Internet and can be accessed on the company's website
Mi è entrato un segnale di acquisto su quest'azione, di entrare in apertura, con stop 10.50 per i più rigidi e 9.90 per quelli che amano di più il rischio!! Purtroppo ho un problema, non riesco a reperire un grafico aggiornato di questo titolo AMRI. Se qualcuno mi fa il grosso piacere di metterlo sul forum gliene sono molto grato!!!

Comunque target 11,50, nonchè massimi di Marzo, e se violato questo livello target finale sui 13 $

Grazie mille per il vostro sempre prezioso aiuto!!
perde il 22% ma non vedo notizie su lycos:rolleyes:
potrebbe andare a 9


  • MChartISAPI.png
    22,7 KB · Visite: 39